MSB 5.24% $1.11 mesoblast limited

Ryoncil: ODAC/FDA Meeting Discussion, page-1991

  1. 473 Posts.
    lightbulb Created with Sketch. 800
    Remember Lassman wants the FDA to reject our BLA? They wanted us to do a proper randomized control trial? KARMA is a bieetch, I believe it is likely that the FDA will approve Ryoncil for children SR aGVHD, but I could see a phase 4 RCT trial to treat the adult population as one of the requirement for approval. The Lassman wanted a RCT, i think they will get it!!! And as I mentioned earlier Jakafi's efficacy is rubbish especially for those patients with grade III and IV disease. I think SI is more than happy to conduct the extension trial together with the FDA.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.11
Change
0.055(5.24%)
Mkt cap ! $1.261B
Open High Low Value Volume
$1.05 $1.13 $1.04 $6.781M 6.207M

Buyers (Bids)

No. Vol. Price($)
3 43856 $1.11
 

Sellers (Offers)

Price($) Vol. No.
$1.11 66000 1
View Market Depth
Last trade - 16.10pm 05/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.